AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
tradipitant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| neurokinin NK1 (substance P) receptor antagonist | 5803 | 622370-35-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Tradipitant is a selective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1) receptors. Tradipitant does not have affinity for NK2 and NK3, serotonin (5-HT3), dopamine (D2), cholinergic, or histamine (H1) receptors. Tradipitant has been shown in animal models to inhibit drug induced emesis. Human Positron Emission Tomography (PET) studies with tradipitant have shown that tradipitant crosses the blood brain barrier and occupies brain NK-1 receptors. The exact mechanism by which tradipitant exerts its therapeutic effect is not fully established.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 2025 | FDA | Vanda Pharmaceuticals |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000932 | Antiemetics |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Prevention of vomiting induced by motion | indication | 37031009 | DOID:2951 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 85MG | NEREUS | VANDA PHARMS INC | N220152 | Dec. 30, 2025 | RX | CAPSULE | ORAL | 10772880 | March 4, 2036 | PREVENTION OF VOMITING INDUCED BY MOTION IN ADULTS BY ADMINISTERING TRADIPITANT |
| 85MG | NEREUS | VANDA PHARMS INC | N220152 | Dec. 30, 2025 | RX | CAPSULE | ORAL | 10821099 | March 4, 2036 | PREVENTION OF VOMITING INDUCED BY MOTION IN ADULTS BY ADMINISTERING TRADIPITANT |
| 85MG | NEREUS | VANDA PHARMS INC | N220152 | Dec. 30, 2025 | RX | CAPSULE | ORAL | 11324735 | March 4, 2036 | PREVENTION OF VOMITING INDUCED BY MOTION IN ADULTS BY ADMINISTERING TRADIPITANT |
| 85MG | NEREUS | VANDA PHARMS INC | N220152 | Dec. 30, 2025 | RX | CAPSULE | ORAL | 12318375 | Aug. 9, 2036 | PREVENTION OF VOMITING INDUCED BY MOTION IN ADULTS BY ADMINISTERING TRADIPITANT |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 85MG | NEREUS | VANDA PHARMS INC | N220152 | Dec. 30, 2025 | RX | CAPSULE | ORAL | Dec. 30, 2030 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Substance-P receptor | GPCR | INHIBITOR | Ki | 10.62 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEMBL3544984 | ChEMBL_ID |
| C000731911 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB12580 | DRUGBANK_ID |
| 4044674 | VANDF |
| C4519147 | UMLSCUI |
| CHEBI:747212 | CHEBI |
| 9996 | INN_ID |
| 9916461 | PUBCHEM_CID |
| 400326 | MMSL |
| 44620 | MMSL |
| d10358 | MMSL |
| 020320 | NDDF |
| 9278 | IUPHAR_LIGAND_ID |
| NY0COC51FI | UNII |
| 2739506 | RXNORM |
| C527551 | MESH_SUPPLEMENTAL_RECORD_UI |
| D11728 | KEGG_DRUG |
| NY0COC51FI | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| NEREUS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43068-585 | CAPSULE | 85 mg | ORAL | NDA | 24 sections |